Seed · Biotech · Cologne, Germany · Founded 2020 · 10–16 employees
PROSION Therapeutics is a drug development company with a proprietary platform that addresses previously undruggable targets through LEGO-like chemical building blocks called ProMs. The company focuses on developing small molecule inhibitors for proline-rich-motif binding domains linked to cancer, Alzheimer's, diabetes, and cardiovascular diseases. They have secured €2.5 million from the European Innovation Council Accelerator and additional seed funding from Freigeist Capital. The company has demonstrated significant cancer inhibition in preclinical studies on triple-negative breast cancer and pancreatic cancer.
No open roles listed right now.